Cargando…

Monoclonal Antibody Therapy for the Treatment of Interstitial Cystitis

An emerging theory regarding the potentially autoimmune nature of painful bladder syndrome/interstitial cystitis (PBS/IC) had led to several studies being conducted to assess the possible therapeutic effect of immunotherapeutic options for PBS/IC. This review presents the available evidence regardin...

Descripción completa

Detalles Bibliográficos
Autores principales: Mykoniatis, Ioannis, Tsiakaras, Stavros, Samarinas, Michael, Anastasiadis, Anastasios, Symeonidis, Evangelos N, Sountoulides, Petros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9129098/
https://www.ncbi.nlm.nih.gov/pubmed/35619987
http://dx.doi.org/10.2147/BTT.S290286
_version_ 1784712689443930112
author Mykoniatis, Ioannis
Tsiakaras, Stavros
Samarinas, Michael
Anastasiadis, Anastasios
Symeonidis, Evangelos N
Sountoulides, Petros
author_facet Mykoniatis, Ioannis
Tsiakaras, Stavros
Samarinas, Michael
Anastasiadis, Anastasios
Symeonidis, Evangelos N
Sountoulides, Petros
author_sort Mykoniatis, Ioannis
collection PubMed
description An emerging theory regarding the potentially autoimmune nature of painful bladder syndrome/interstitial cystitis (PBS/IC) had led to several studies being conducted to assess the possible therapeutic effect of immunotherapeutic options for PBS/IC. This review presents the available evidence regarding the potential autoimmunity-based pathogenesis of PBS/IC and focuses on a main representative of the immunotherapeutic modalities for PBS/IC, aiming to summarize, evaluate, and present available data regarding the potential therapeutic role of monoclonal antibodies for PBS/IC patients. A non-systematic narrative and interpretative literature review was performed. The monoclonal antibodies included in the review were the anti-tumor necrosis factor-α (anti-TNF-α) agents adalimumab, which showed no difference compared to placebo, and certolizumab pegol, which showed statistically important differences in all outcome measures compared to placebo at the 18-week follow-up visit. Anti-nerve growth factor (anti-NGF) agents were also reviewed, including tanezumab, which showed both positive and negative efficacy results compared to placebo, and fulranumab, the study of which was discontinued owing to adverse events. In summary, monoclonal antibody therapy remains to be further researched in order for it to be proposed as a promising future treatment option for PBS/IC.
format Online
Article
Text
id pubmed-9129098
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-91290982022-05-25 Monoclonal Antibody Therapy for the Treatment of Interstitial Cystitis Mykoniatis, Ioannis Tsiakaras, Stavros Samarinas, Michael Anastasiadis, Anastasios Symeonidis, Evangelos N Sountoulides, Petros Biologics Review An emerging theory regarding the potentially autoimmune nature of painful bladder syndrome/interstitial cystitis (PBS/IC) had led to several studies being conducted to assess the possible therapeutic effect of immunotherapeutic options for PBS/IC. This review presents the available evidence regarding the potential autoimmunity-based pathogenesis of PBS/IC and focuses on a main representative of the immunotherapeutic modalities for PBS/IC, aiming to summarize, evaluate, and present available data regarding the potential therapeutic role of monoclonal antibodies for PBS/IC patients. A non-systematic narrative and interpretative literature review was performed. The monoclonal antibodies included in the review were the anti-tumor necrosis factor-α (anti-TNF-α) agents adalimumab, which showed no difference compared to placebo, and certolizumab pegol, which showed statistically important differences in all outcome measures compared to placebo at the 18-week follow-up visit. Anti-nerve growth factor (anti-NGF) agents were also reviewed, including tanezumab, which showed both positive and negative efficacy results compared to placebo, and fulranumab, the study of which was discontinued owing to adverse events. In summary, monoclonal antibody therapy remains to be further researched in order for it to be proposed as a promising future treatment option for PBS/IC. Dove 2022-05-20 /pmc/articles/PMC9129098/ /pubmed/35619987 http://dx.doi.org/10.2147/BTT.S290286 Text en © 2022 Mykoniatis et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Mykoniatis, Ioannis
Tsiakaras, Stavros
Samarinas, Michael
Anastasiadis, Anastasios
Symeonidis, Evangelos N
Sountoulides, Petros
Monoclonal Antibody Therapy for the Treatment of Interstitial Cystitis
title Monoclonal Antibody Therapy for the Treatment of Interstitial Cystitis
title_full Monoclonal Antibody Therapy for the Treatment of Interstitial Cystitis
title_fullStr Monoclonal Antibody Therapy for the Treatment of Interstitial Cystitis
title_full_unstemmed Monoclonal Antibody Therapy for the Treatment of Interstitial Cystitis
title_short Monoclonal Antibody Therapy for the Treatment of Interstitial Cystitis
title_sort monoclonal antibody therapy for the treatment of interstitial cystitis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9129098/
https://www.ncbi.nlm.nih.gov/pubmed/35619987
http://dx.doi.org/10.2147/BTT.S290286
work_keys_str_mv AT mykoniatisioannis monoclonalantibodytherapyforthetreatmentofinterstitialcystitis
AT tsiakarasstavros monoclonalantibodytherapyforthetreatmentofinterstitialcystitis
AT samarinasmichael monoclonalantibodytherapyforthetreatmentofinterstitialcystitis
AT anastasiadisanastasios monoclonalantibodytherapyforthetreatmentofinterstitialcystitis
AT symeonidisevangelosn monoclonalantibodytherapyforthetreatmentofinterstitialcystitis
AT sountoulidespetros monoclonalantibodytherapyforthetreatmentofinterstitialcystitis